Drugs and Biotech: "Poised for a Pretty Strong Year"

Fidelity's Yolanda McGettigan explains why she remains bullish about a sector that has produced only disappointments so far

By Robert Barker

To continue reading this article you must be a Bloomberg Professional Service Subscriber.